CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating expenses:
Research and development	$ 12,705,000	$ 3,951,000
Acquired in-process research and development	80,538,000	0
General and administrative	14,724,000	3,297,000
Transaction costs	5,765,000	0
Change in fair value of contingent consideration	(180,000)	19,240,000
Total operating expenses	113,552,000	26,488,000
Loss from operations	(113,552,000)	(26,488,000)
Other expenses:
Loss on sale of NTN assets	(9,648,000)	0
Other income (expense), net	899,000	(43,000)
Total other expenses, net	(8,749,000)	(43,000)
Loss before income taxes	(122,301,000)	(26,531,000)
Provision for income taxes	(5,000)	0
Net loss	(122,306,000)	(26,531,000)
Series A preferred stock dividend	(16,000)	0
Net loss attributable to common stockholders	$ (122,322,000)	$ (26,531,000)
Net loss per common share - basic (in dollars per share)	$ (2.82)	$ (1.51)
Net loss per common share - diluted (in dollars per share)	$ (2.82)	$ (1.51)
Weighted average number of shares outstanding - basic (in shares)	43,306	17,588
Weighted average number of shares outstanding - diluted (in shares)	43,306	17,588